Cancer Tumor Marker test

002

Tumor marker is a collective term for substances that become markers of cancer cells . In other words, it is "a substance that a cancer cell produces, or a substance that a non-cancer cell produces in response to the presence of cancer in the body. By detecting them with tissues, body fluids, excretions, etc., It is defined as "a guide for knowing the existence, kind, progression". Therefore, there is a reference value which is a boundary line that distinguishes whether the measured value is a normal region or an abnormal region, and this reference value varies depending on the measuring method and measuring equipment.
Tumor markers are also used as screening (sieving) tests to detect cancer early. However, it may not be detected even if there is cancer, and it may increase even for diseases other than cancer, so it is premature to decide it as a definitive index and it is comprehensive by combining imaging diagnosis and biopsy It is a thing to judge.
Rather, it is considered to be useful in view of follow-up observation during treatment and recurrence check. In addition, since it is possible to expect a more reliable diagnosis by examining several tumor markers which are indicators of cancer of an organ, it is often used to inspect multiple tumor marker tests in combination.

SCC

Squamous cell carcinoma (cell type) has a high positive rate and shows high values in uterine cancer, lung cancer, skin cancer, esophageal cancer, bladder cancer and the like. It also reflects the progress of the tumor well, so it is useful for the treatment effect and follow-up of cancer. It is used in conjunction with other tumor markers such as CEA, SLX, NSE and others.

PSA (male only)

It is a tumor marker specifically found in the prostate, and it is positioned as a first screening examination when prostate cancer is suspected.
In addition, it sensitively reflects the progress of cancer, so it is used for early detection of the prostate cancer, estimation of disease, treatment effect determination, prognosis prediction.

CEA

It is a type of protein found only in digestive cells, but it is also produced from tissues in which cancer cells are proliferating. It is widely used as a screening examination of gastrointestinal (digestive system) cancer and also is used for follow-up after cancer treatment, early detection of recurrence and metastasis.

AFP

It is a type of protein found in the serum of fetuses, which disappears after birth but increases when liver cancer develops. It is measured along with blood biochemical tests such as GOT and GPT, and is used as a screening test of liver cancer.

CA19-9

It is a highly specific tumor marker in gastrointestinal cancer, especially pancreatic cancer. Although it is not useful for early detection, it is useful for examining therapeutic effects.

CA125 (female only)

Although it is a tumor marker of the digestive system, CA 125 is a tumor marker indicating a unique response to ovarian tumor and uterine cancer. Because reagents that respond to mucinous antigens, which are glycoproteins generated from the epithelium of the ovary covering the fetus' body, are used , CA 125 is used with CA 602 as a test for gynecological diseases, especially ovarian cancer.

CA602 (female only)

It is useful as a marker for epithelial ovarian cancer and is used for the diagnosis of cancer, early detection of recurrence after surgery, monitoring of treatment and so on. As with CA 125, it is the first tumor marker to be checked if ovarian cancer is suspected.

SLX

It is a tumor marker that detects glycan produced by cancer cells. It increases to a wide range of cancers including mainly lung cancer, gastrointestinal cancer, breast cancer, ovarian cancer, and false positive rate in non-cancer disease is low. In addition, it is characterized by relatively high cancer specificity

CA15-3 (female only)

It is used for the screening test of breast cancer because there is specificity in breast cancer. Although early breast cancer shows little positive, it is a highly useful tumor marker for follow-up after surgery because it has a high positive rate for metastatic breast cancer.